Edition:
United Kingdom

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

50.25SEK
18 Dec 2017
Change (% chg)

0.35kr (+0.70%)
Prev Close
49.90kr
Open
50.00kr
Day's High
51.50kr
Day's Low
49.90kr
Volume
62,007
Avg. Vol
66,013
52-wk High
102.00kr
52-wk Low
47.20kr

Latest Key Developments (Source: Significant Developments)

Medivir says Janssen to terminate Simeprevir license by June 2018
Sunday, 10 Dec 2017 

Dec 10 (Reuters) - Medivir Ab ::MEDIVIR ANNOUNCES JANSSEN DECISION TO TERMINATE ITS SIMEPREVIR LICENSE EFFECTIVE JUNE 2018.SAYS JANSSEN PHARMACEUTICALS INC. HAS DECIDED TO TERMINATE THE LICENSE THAT IT HOLDS FOR SIMEPREVIR DUE TO JANSSEN'S ASSESSMENT OF MARKET DEMAND.  Full Article

Medivir announces new cancer project
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Medivir Ab :Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform.Says Leukotide project is intended to deliver a new drug for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.Says aim of the Leukotide project is to develop a better tolerated and more effective agent that can lead to improved treatment outcomes for patients with AML and other hematological cancers.  Full Article

Medivir Q3 EBITDA loss widens
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Medivir :Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​.Q3 ‍loss before interest, tax, depreciation and amortisation (EBITDA) totalled SEK -78.3 million (-53.9 m)​.  Full Article

Medivir receives FDA fast track designation for MIV-711 for treatment of OA
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Medivir :Medivir receives FDA fast track designation for MIV-711 for the treatment of OA.  Full Article

Medivir reports positive data in remetinostat phase II trial ‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Medivir Ab :Medivir says ‍remetinostat phase ii data demonstrate efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage mf-type ctcl​.phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions.  Full Article

Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Medivir :Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C.Says ongoing phase ii studies with JNJ-4178 will continue as planned, but there will be no additional development thereafter..Says discontinuation of development of JNJ-4178 does not affect ongoing partnership with Janssen on Olysio (simeprevir), or existing licensing agreement with Janssen in which simeprevir is included.  Full Article

Medivir says names Christine Lind as new CEO
Thursday, 9 Feb 2017 

Medivir AB :Says Christine Lind new ceo of medivir ab effective 1 april 2017.  Full Article

Medivir says fusion inhibitor MIV-323 enters non-clinical development
Wednesday, 14 Dec 2016 

Medivir AB :Medivir's fusion inhibitor for the treatment of respiratory syncytial virus infection, MIV-323, enters non-clinical development.  Full Article

BRIEF-Karo Pharma says acquires Biophausia from Medivir
Tuesday, 1 Nov 2016 

Karo Pharma AB : Says acquires Biophausia (nordic brands) from Medivir .Says the purchase price will be SEK 908 million.  Full Article

Karo pharma ab says acquires biophausia (nordic brands)
Tuesday, 1 Nov 2016 

Karo Pharma AB : Says acquires Biophausia (nordic brands) from Medivir .Says the purchase price will be SEK 908 million.  Full Article

BRIEF-Medivir says Janssen to terminate Simeprevir license by June 2018

* MEDIVIR ANNOUNCES JANSSEN DECISION TO TERMINATE ITS SIMEPREVIR LICENSE EFFECTIVE JUNE 2018